Search results
J&J, Bristol Myers lose challenges to US drug price negotiation program
Reuters via Yahoo Finance· 6 minutes agoA U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with ...
Bristol-Myers Squibb stock target cut on cost cutting measures By Investing.com
Investing.com· 5 hours agoOn Monday, Deutsche Bank (ETR:DBKGn) adjusted its outlook on Bristol-Myers Squibb Co. shares...
Why Bristol Myers Squibb Stock Is Sinking Today
Motley Fool via Yahoo Finance· 4 days agoShares of Bristol Myers Squibb (NYSE: BMY) were down 8.3% as of 11:19 a.m. ET on Thursday. The sell-off came after the big drugmaker announced its...
Bristol Myers Squibb enlists Cellares amid industry manufacturing “land grab”
BioPharma-Reporter· 8 hours agoCellares has received a vote of confidence in its integrated and automated cell therapy factories as...
Analyzing Bristol-Myers Squibb Co.
Knox Daily· 7 hours agoBristol-Myers Squibb Co.’s filing revealed that its Chief Executive Officer BOERNER CHRISTOPHER S. acquired Company’s shares for reported $99560.0 on Dec 05 ’23. In the deal valued at $49.78 ...
Bristol-Myers Squibb Expected to Earn Q2 2024 Earnings of $1.76 Per Share (NYSE:BMY)
ETF DAILY NEWS· 20 hours agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Equities research analysts at Leerink Partnrs lowered their Q2 2024 EPS estimates for shares of Bristol-Myers Squibb in a report issued on Thursday ...
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patents
Quartz· 4 days agoPharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug...
After 'reset,' Flagship startup lands $1.8B Bristol Myers Squibb deal - Boston Business Journal
The Business Journals· 12 hours agoTorben Straight Nissen took over the reins of Repertoire Immune Medicines at the tail end of 2022,...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to...
FOX 4 Kansas City· 12 hours agoRepertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year ...
Is Bristol Myers Squibb Stock a Millionaire Maker?
Motley Fool via Yahoo Finance· 4 days agoMany top healthcare stocks provide investors with long-term stability, promising growth prospects, and in some cases even a dividend. Yet, investors...
